NCPC(600812.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
NCPC
600812.SH
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China.
2.768 T
600812.SHMarket value -Rank by Market Cap -/-

Financial Score

21/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking109/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.93%C
    • Profit Margin1.83%C
    • Gross Margin28.95%C
  • Growth ScoreD
    • Revenue YoY-10.78%E
    • Net Profit YoY-3.18%C
    • Total Assets YoY-2.46%D
    • Net Assets YoY2.70%C
  • Cash ScoreC
    • Cash Flow Margin727.71%A
    • OCF YoY-10.78%E
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreD
    • Gearing Ratio67.68%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NCPC: In the third quarter, the net profit attributable to the parent company was 35.0066 million yuan, an increase of 14.85% year-on-year

    Zhitong·
    SH
    600812
    -1.04%
    Zhitong·
    SH
    600812
    -1.04%

    NCPC: Wholly-owned subsidiary receives approval notice for the listing application of Cefoperazone chemical raw materials

    Zhitong·
    SH
    600812
    -1.04%
    Zhitong·
    SH
    600812
    -1.04%

    NCPC: Southern Company Obtains Drug Registration Certificate

    Zhitong·
    SH
    600812
    -1.04%
    Zhitong·
    SH
    600812
    -1.04%

    NCPC has obtained the drug registration certificate for injectable vancomycin hydrochloride (0.5g)

    Zhitong·
    SH
    600812
    -1.04%
    Zhitong·
    SH
    600812
    -1.04%

    NCPC released its semi-annual performance report, with a net profit attributable to the parent company of 123 million yuan, a year-on-year increase of 71.56%

    Zhitong·
    SH
    600812
    -1.04%
    Zhitong·
    SH
    600812
    -1.04%
    © 2026 Longbridge｜Disclaimer